Notification for the Submission of Safety and Efficacy of FDC permitted to manufacture but not approved by DCGI
According to DCG (I) file No. 4-01/2013-DC (Misc 13-PSC) dated 15 Jan 2013, In respect of FDC Falling under definition of “New Drug” licensed by state licensing Authorities before 1.10.12, without the permission of DCG (I), it has been decided that the DCG (I) will ask all the state drug controllers to ask the concerned manufacturers to prove the Safety and Efficacy of such FDCs before CDSCO within a period of 18 months, failing which such FDCs will be considered for being prohibited for manufacture and marketing in the country.
The new FDCs, if any, licensed by the state licensing authorities after 01.10.12 without approval of DCG(I), the same will be considered for being prohibited for manufacture and marketing in the country.
Recent Posts
India as a Cosmetic Manufacturing Hub: CDSCO, BIS, and the Regulatory Enablers for Global Manufacturers
The Strategic Shift For most global Cosmetic brands, India’s regulatory journey has begun with import registration — the COS-2 pathway explored throughout this series. But for a growing ..
Post-Market Surveillance Under Medical Device Rules, 2017
Regulatory approval is often treated as the finish line. In reality, for Medical Device and IVD manufacturers in India, it marks the start of an equally demanding obligation: Post-Market Surveillance ..
How to Sequence Global and India Market Entry for Medical Devices Without Creating Regulatory Rework
One of the most avoidable and expensive mistakes in Medical Device commercialisation is Regulatory rework — the process of going back to redo documentation, testing, or submissions because the..
Need Help?
Submit your EnquiryOffice Locations
- Delhi
- Bangalore
- USA
- Singapore